Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E23.47 EPS (ttm)16.61 Insider Own0.50% Shs Outstand102.69M Perf Week1.48%
Market Cap40.03B Forward P/E17.68 EPS next Y22.05 Insider Trans-27.52% Shs Float75.74M Perf Month0.67%
Income1.92B PEG2.76 EPS next Q5.17 Inst Own72.50% Short Float3.46% Perf Quarter6.45%
Sales6.20B P/S6.45 EPS this Y70.80% Inst Trans0.05% Short Ratio3.81 Perf Half Y23.36%
Book/sh66.66 P/B5.85 EPS next Y7.94% ROA17.30% Target Price407.86 Perf Year-11.59%
Cash/sh16.39 P/C23.78 EPS next 5Y8.50% ROE24.50% 52W Range281.89 - 443.00 Perf YTD3.69%
Dividend- P/FCF24.46 EPS past 5Y14.30% ROI22.30% 52W High-12.00% Beta1.23
Dividend %- Quick Ratio3.10 Sales past 5Y33.60% Gross Margin93.30% 52W Low38.29% ATR11.94
Employees6200 Current Ratio3.60 Sales Q/Q9.40% Oper. Margin36.90% RSI (14)50.03 Volatility3.19% 2.98%
OptionableYes Debt/Eq0.00 EPS Q/Q44.30% Profit Margin25.70% Rel Volume1.05 Prev Close395.22
ShortableYes LT Debt/Eq0.10 EarningsNov 06 BMO Payout0.00% Avg Volume687.57K Price389.83
Recom2.60 SMA20-0.66% SMA500.28% SMA20011.52% Volume721,459 Change-1.36%
Oct-01-18Initiated Cantor Fitzgerald Neutral $415
May-04-18Reiterated Canaccord Genuity Hold $356 → $304
Apr-09-18Downgrade Raymond James Outperform → Mkt Perform
Feb-21-18Downgrade Canaccord Genuity Buy → Hold $522 → $356
Jan-09-18Reiterated Citigroup Neutral $380 → $388
Dec-01-17Downgrade Citigroup Buy → Neutral $480 → $380
Nov-09-17Reiterated RBC Capital Mkts Sector Perform $473 → $425
Oct-24-17Resumed Guggenheim Buy $540
Oct-20-17Downgrade Barclays Equal Weight → Underweight $450 → $395
Sep-29-17Resumed Piper Jaffray Overweight $540
Sep-15-17Initiated RBC Capital Mkts Sector Perform $475
Sep-06-17Resumed Raymond James Outperform $566
Aug-17-17Initiated Evercore ISI Outperform $605
Aug-04-17Reiterated UBS Buy $489 → $535
Aug-01-17Downgrade Robert W. Baird Neutral → Underperform $408
Jun-30-17Reiterated BTIG Research Buy $480 → $540
Jun-26-17Downgrade Bernstein Outperform → Mkt Perform
Jun-20-17Reiterated Piper Jaffray Overweight $446 → $557
May-05-17Upgrade Canaccord Genuity Hold → Buy $375 → $484
Mar-29-17Reiterated UBS Buy $435 → $446
Oct-19-18 08:57PM  Sanofi drug Dupixent wins U.S. FDA approval to treat asthma Reuters
06:03PM  Sanofi drug Dupixent wins U.S. FDA approval to treat asthma Reuters
05:59PM  Sanofi: FDA approves asthma indication for Dupixent® (dupilumab) GlobeNewswire
05:55PM  FDA approves asthsma indication for Dupixent® (dupilumab) PR Newswire
05:55PM  FDA Approves Asthma Indication for Dupixent® (dupilumab) PR Newswire
07:00AM  Kevzara® (sarilumab) Data at the 2018 ACR/ARHP Annual Meeting Provide Additional Insight on Safety and Efficacy in Rheumatoid Arthritis PR Newswire
Oct-18-18 10:10AM  Why the Earnings Surprise Streak Could Continue for Regeneron (REGN) Zacks
Oct-17-18 09:11AM  Regeneron's Dupixent Meets Goals in Nasal Polyps Studies Zacks
Oct-16-18 12:08PM  4 Strong Stocks to Buy That Double As Big Takeover Targets InvestorPlace +5.55%
08:00AM  Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps PR Newswire
01:20AM  Sanofi, Regeneron say late-stage Dupixent trials show positive results Reuters
01:01AM  Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps GlobeNewswire
12:59AM  Dupixent® (dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients with Chronic Rhinosinusitis with Nasal Polyps PR Newswire
Oct-10-18 11:38AM  5 Healthcare Stocks to Buy for Complete Portfolio Wellness InvestorPlace
Oct-09-18 10:45AM  ARWR Stock Sinks After Signing a Big Collaboration Deal InvestorPlace
Oct-08-18 08:45PM  How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support Investor's Business Daily
06:05PM  Libtayo® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation PR Newswire
05:14PM  3 Top Biotech Stocks to Buy in October Motley Fool
09:30AM  Regeneron to Report Third Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2018 PR Newswire
Oct-05-18 08:55AM  Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Financial Strength Analysis Simply Wall St.
Oct-03-18 10:54AM  Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs Zacks
Oct-01-18 04:01PM  Drugmakers are finding new solutions to food allergies CNBC Videos
11:35AM  Sanofi/Regeneron's Cemiplimab Wins FDA Nod for Skin Cancer Zacks
Sep-28-18 05:34PM  Sanofi, Regeneron skin cancer drug gets FDA nod Reuters
05:15PM  Regeneron, Sanofi Win Approval for First Immuno-Oncology Drug Bloomberg
05:05PM  Sanofi, Regeneron skin cancer drug gets FDA nod Reuters
04:51PM  Sanofi, Regeneron have skin-cancer drug approved MarketWatch
04:40PM  FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma PR Newswire
04:39PM  FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma PR Newswire
08:30AM  Today's Research Reports on Trending Tickers: bluebird bio and Regeneron Pharmaceuticals ACCESSWIRE
Sep-27-18 02:46PM  With life-threatening food allergies on the rise, drug companies ramp up new approaches CNBC
01:23PM  Regeneron buys Autotask headquarters for $13.6 million American City Business Journals
09:30AM  Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year? Zacks
Sep-26-18 10:17PM  3 Drugmakers Not Pleased With Amarin's Fish Oil Triumph Motley Fool
09:15AM  My Favorite Large-Cap Biotech Stock to Buy Now Motley Fool
Sep-25-18 10:52AM  FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study Zacks
10:44AM  FDA Lifts Clinical Hold on Sarepta's DMD Gene Therapy Program Zacks
09:17AM featured highlights include: Regeneron, AT&T, AMETEK, Hershey Company and BGC Zacks
Sep-24-18 04:43PM  CHMP Reconfirms Negative Opinion for Sarepta's Exondys Zacks
04:00PM  Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar Zacks
Sep-21-18 06:12PM  FDA Confirms Positive Safety Profile of Acadia's Nuplazid Zacks
Sep-20-18 03:12PM  The 7 Best Biotech Stocks for Investors Who Hate Risk Kiplinger
07:35AM highlights: G-III Apparel Group, Target, Regeneron Pharmaceuticals, AMETEK and Xilinx Zacks
07:32AM  The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences Zacks
Sep-19-18 05:05PM  5 Stocks Primed To Fall Lower In The Coming Days Benzinga
11:01AM  Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success Zacks
09:08AM  5 Stocks Near 52-Week High With Scope for Further Upside Zacks
Sep-18-18 06:29PM  Regeneron Gains on Eylea, Dupixent and Pipeline Progress Zacks
01:35AM  Sanofi pledges to keep up its restructuring efforts Reuters
Sep-17-18 10:02AM  Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis Zacks
09:00AM  Time to Focus on Regeneron Pharmaceuticals (REGN) for Strong Earnings Growth Potential Zacks
Sep-15-18 02:04AM  Sanofi: Positive Phase 3 results presented for Dupixent® (dupilumab) GlobeNewswire
01:59AM  Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis PR Newswire
Sep-14-18 07:18AM  Sanofi pledges to keep up its restructuring efforts Reuters
Sep-13-18 07:00AM  FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy PR Newswire
Sep-12-18 06:00PM  Bluebird Bio Stock May Have Upside of at Least 60 Percent InvestorPlace
10:41AM  Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars Zacks
09:55AM  Regeneron/Sanofi's sBLA for Praluent to be Reviewed by FDA Zacks
08:00AM  FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events PR Newswire
01:02AM  FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events GlobeNewswire
12:59AM  FDA to Review Supplemental Biologics License Application for Praluent® (alirocumab)Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events PR Newswire
Sep-07-18 02:10PM  Arrowhead Stock Is Not Done Rallying After Its 38% Jump InvestorPlace
Aug-31-18 07:00PM  How to Invest at Every Age: Cramer's 'Mad Money' Recap (Fri. 8/31/18)
06:30PM  Sizzling Stocks: 4 trades CNBC Videos
05:50PM  These surprising stocks are soaring this summer CNBC Videos
01:13PM  How Confident Are Insiders About Regeneron Pharmaceuticals Inc (NASDAQ:REGN)? Simply Wall St.
08:00AM  Market Trends Toward New Normal in Sykes Enterprises, Carnival, Covenant Transportation Group, Synergy Pharmaceuticals, Regeneron Pharmaceuticals, and Minerals Technologies Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Aug-30-18 09:30AM  Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year? Zacks
08:00AM  Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE
Aug-29-18 02:00PM  3 Stocks That May Lead a Massive Biotech Breakout Investopedia
Aug-28-18 10:53AM  Top Stock Reports for Oracle, Intuit & Regeneron Pharmaceuticals Zacks
Aug-27-18 12:14PM  Play The Future of Gene Therapy With These 5 Biotech Stocks InvestorPlace
Aug-24-18 09:30AM  Regeneron Announces Upcoming Investor Conference Presentation PR Newswire
08:47AM  The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict Benzinga
Aug-23-18 09:18AM  4 Biotech Stocks Investors Can Bet on Post Solid Q2 Earnings Zacks
09:14AM  Top-Ranked Stocks That Crushed S&P 500 in Longest Bull Run Zacks
Aug-22-18 11:43AM  Biotech Stock Roundup: Label Expansion of Regeneron's Eylea, Vertex's Kalydeco Zacks
Aug-21-18 10:41AM  5 Low-Cost Biotech Stocks With High Levels of Growth InvestorPlace
Aug-20-18 03:08PM  The Week Ahead: Alibaba, More Retail Earnings Take Center Stage Benzinga
11:51AM  Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose Zacks
Aug-17-18 01:55PM  Edited Transcript of REGN earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
09:01AM  Regeneron, Teva Announce Positive Data on Osteoarthritis Drug Zacks
07:51AM  Regeneron's anti-blindness drug approved for less frequent treatments Reuters
07:00AM  FDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration PR Newswire
Aug-16-18 07:00AM  Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip Business Wire
07:00AM  Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip PR Newswire
Aug-14-18 09:49AM  Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD Zacks
08:43AM  Time to Focus on Regeneron Pharmaceuticals (REGN) for Strong Earnings Growth Potential Zacks
Aug-13-18 05:00PM  Know This Sell Signal: When Stock Leaders Stage Big Downside Reversals Investor's Business Daily
07:00AM  Regeneron Provides Regulatory Update on EYLEA® (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration PR Newswire
Aug-09-18 10:25PM  Carl Icahn Fires Shots at Express Scripts Motley Fool
02:50PM  7 "Zombie Stocks" That Are Coming Back to Life Kiplinger
Aug-08-18 07:52AM  Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges Zacks
Aug-07-18 11:30AM  Why this company's Durham outpost may benefit from $100M investment American City Business Journals
Aug-06-18 04:15PM  Can These Biotech Companies Catch Novartis, Gilead In CAR-T? Investor's Business Daily
01:30PM  T-Mobile-Sprint, Pepsi CEO Departs, Jamie Dimon's Latest Wisdom, & More | Free Lunch Zacks
11:59AM  Small Biotechs See Big Gains as Bluebird, Intercept Fly
11:44AM  Why Is Bluebird Bio (BLUE) Stock Gaining Today? Zacks
11:02AM  Regeneron To Make $100M bluebird bio Investment In Cancer Research Collaboration Benzinga
09:39AM  Bluebird Bio stock lifts on Regeneron collaboration, $100 mln investment MarketWatch
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDSTEIN JOSEPH LDirectorSep 28Option Exercise273.67709194,03212,709Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 28Sale410.00709290,69012,000Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 27Option Exercise273.672,000547,34014,000Oct 01 04:06 PM
BROWN MICHAEL SDirectorSep 27Option Exercise273.672,000547,3402,000Sep 28 04:35 PM
BROWN MICHAEL SDirectorSep 27Sale392.262,000784,5240Sep 28 04:35 PM
GOLDSTEIN JOSEPH LDirectorSep 27Sale400.002,000800,00012,000Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 24Option Exercise273.672,000547,34013,000Sep 25 04:05 PM
GOLDSTEIN JOSEPH LDirectorSep 24Sale388.652,000777,29012,000Sep 25 04:05 PM
Fenimore Christopher R.VP ControllerAug 30Option Exercise21.25501,063200Aug 31 04:02 PM
BROWN MICHAEL SDirectorAug 22Option Exercise177.821,500266,7301,500Aug 23 04:01 PM
BROWN MICHAEL SDirectorAug 22Sale380.491,500570,7350Aug 23 04:01 PM
VAGELOS P ROYChairman of the BoardAug 20Option Exercise21.252104,463400,057Aug 21 04:55 PM
GOLDSTEIN JOSEPH LDirectorAug 02Option Exercise57.112,000114,22014,000Aug 03 04:03 PM
GOLDSTEIN JOSEPH LDirectorAug 02Sale380.002,000760,00012,000Aug 03 04:03 PM
VAGELOS P ROYChairman of the BoardJul 10Sale367.2274,67027,420,277399,847Jul 11 04:04 PM
VAGELOS P ROYChairman of the BoardJul 09Option Exercise16.80153,2742,575,003553,121Jul 11 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 06Option Exercise57.112,000114,22014,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 06Sale370.002,000740,00012,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 05Option Exercise57.112,000114,22014,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 05Sale360.002,000720,00012,000Jul 09 04:04 PM
VAGELOS P ROYChairman of the BoardJun 21Sale327.8774,71024,495,410399,847Jun 22 04:03 PM
VAGELOS P ROYChairman of the BoardJun 20Option Exercise16.80153,2742,575,003553,121Jun 22 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 24Sale295.0911,4073,366,09231,973May 25 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 23Option Exercise30.6326,736818,92458,709May 25 04:03 PM
SING GEORGE LDirectorMay 10Sale286.6213,0003,726,000114,772May 11 04:02 PM
SING GEORGE LDirectorMay 09Sale285.297,0001,997,030127,772May 11 04:02 PM
GOLDSTEIN JOSEPH LDirectorMar 19Option Exercise57.112,000114,22014,000Mar 19 04:47 PM
GOLDSTEIN JOSEPH LDirectorMar 19Sale350.022,000700,04012,000Mar 19 04:47 PM
GOLDSTEIN JOSEPH LDirectorMar 14Option Exercise57.112,000114,22014,000Mar 14 04:01 PM
GOLDSTEIN JOSEPH LDirectorMar 14Sale340.002,000680,00012,000Mar 14 04:01 PM
GOLDSTEIN JOSEPH LDirectorFeb 09Sale325.601,000325,60012,000Feb 13 04:01 PM
Fenimore Christopher R.VP ControllerJan 16Option Exercise21.251503,188150Jan 17 04:07 PM
SING GEORGE LDirectorJan 02Option Exercise23.8415,000357,600134,772Jan 03 04:13 PM
YANCOPOULOS GEORGEPresident & CSODec 13Option Exercise21.92195,4384,284,001786,786Dec 13 05:17 PM
SCHLEIFER LEONARD SPresident & CEODec 13Option Exercise21.92250,0005,480,000407,409Dec 13 05:17 PM
VAGELOS P ROYChairman of the BoardDec 11Option Exercise21.92153,9693,375,000483,512Dec 13 04:53 PM